Neuroimmunological aberrations and cerebral asymmetry abnormalities in schizophrenia: Select perspectives on pathogenesis

Clinical Psychopharmacology and Neuroscience

Volumn 12, Issue 1, 2014, Pages 8-18

  Venkatasubramanian, Ganesan ^a   Debnath, Monojit ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Cerebral asymmetry; Estrogens; Immune abnormalities; Neurodevelopment; Schizophrenia

Indexed keywords

ANTIBODY;

BRAIN ASYMMETRY; BRAIN DEVELOPMENT; BRAIN MALFORMATION; HUMAN; IMMUNOPATHOLOGY; NEUROIMMUNOLOGY; PATHOGENESIS; REVIEW; SCHIZOPHRENIA;

EID: 84899556357     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2014.12.1.8     Document Type: Review

References (124)

1. van Os J, Kapur S. Schizophrenia. Lancet 2009;374:635-645.
2. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res 2008;106:89-107.
3. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005;10:434-449. (Pubitemid 40646432)
4. Nicodemus KK, Marenco S, Batten AJ, Vakkalanka R, Egan MF, Straub RE, et al. Serious obstetric complications interact with hypoxia-regulated/vascular- expression genes to influence schizophrenia risk. Mol Psychiatry 2008;13:873-877.
5. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010;167:261-280.
6. Brown AS. Exposure to prenatal infection and risk of schizophrenia. Front Psychiatry 2011;2:63.
7. Madhusudan A, Vogel P, Knuesel I. Impact of prenatal immune system disturbances on brain development. J Neuroimmune Pharmacol 2013;8:79-86.
8. Garay PA, McAllister AK. Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front Synaptic Neurosci 2010;2:136.
9. Geschwind N, Galaburda AM. Cerebral lateralization. Biological mechanisms, associations, and pathology: III. A hypothesis and a program for research. Arch Neurol 1985;42:634-654. (Pubitemid 15062819)
10. Geschwind N, Galaburda AM. Cerebral lateralization. Biological mechanisms, associations, and pathology: II. A hypothesis and a program for research. Arch Neurol 1985;42:521-552. (Pubitemid 15033092)
11. Geschwind N, Galaburda AM. Cerebral lateralization. Biological mechanisms, associations, and pathology: I. A hypothesis and a program for research. Arch Neurol 1985;42:428-459. (Pubitemid 15113010)
12. Stoyanov Z, Nikolova P, Pashalieva I. Season of birth, Geschwind and Galaburda hypothesis, and handedness. Laterality 2011;16:607-619.
13. Stoyanov Z, Decheva L, Pashalieva I, Nikolova P. Brain asymmetry, immunity, handedness. Cent Eur J Med 2012;7:1-8.
14. Tochigi M, Okazaki Y, Kato N, Sasaki T. What causes seasonality of birth in schizophrenia? Neurosci Res 2004;48:1-11. (Pubitemid 37543764)
15. Patterson PH. Neuroscience. Maternal effects on schizophrenia risk. Science 2007;318:576-577. (Pubitemid 350017607)
16. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27:10695-10702. (Pubitemid 47535869)
17. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006;32:200-202.
18. Eyles D, Feldon J, Meyer U. Schizophrenia: do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed developmental rodent models. Transl Psychiatry 2012;2:e81.
19. Ashdown H, Dumont Y, Ng M, Poole S, Boksa P, Luheshi GN. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 2006;11:47-55. (Pubitemid 43251087)
20. Beloosesky R, Gayle DA, Ross MG. Maternal N-acetylcysteine suppresses fetal inflammatory cytokine responses to maternal lipopolysaccharide. Am J Obstet Gynecol 2006;195:1053-1057. (Pubitemid 44415674)
21. Meyer U, Schwendener S, Feldon J, Yee BK. Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res 2006;173:243-257. (Pubitemid 44264888)
22. Dugan LL, Ali SS, Shekhtman G, Roberts AJ, Lucero J, Quick KL, et al. IL-6 mediated degeneration of forebrain GABAergic interneurons and cognitive impairment in aged mice through activation of neuronal NADPH oxidase. PLoS One 2009;4:e5518.
23. Samuelsson AM, Jennische E, Hansson HA, Holmäng A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol 2006;290:R1345-R1356.
24. Carpenter LL, Gawuga CE, Tyrka AR, Lee JK, Anderson GM, Price LH. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010;35:2617-2623.
25. Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res 2013;47:401-406.
26. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-808. (Pubitemid 351410515)
27. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia-a case-control study. J Mol Neurosci 2010;42:112-119.
28. Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008;64:484-490.
29. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 2008;28:13957-13966.
30. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 2007;8:221-232. (Pubitemid 46294661)
31. Sargent IL, Borzychowski AM, Redman CW. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online 2006;13:680-686. (Pubitemid 44760892)
32. Sargent IL, Borzychowski AM, Redman CW. NK cells and human pregnancy - an inflammatory view. Trends Immunol 2006;27:399-404. (Pubitemid 44216188)
33. Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA, et al. Maternal antibrain antibodies in autism. Brain Behav Immun 2007;21:351-357. (Pubitemid 46199109)
34. Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci 2006;26:10709-10716.
35. Murphy PG, Borthwick LA, Altares M, Gauldie J, Kaplan D, Richardson PM. Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. Eur J Neurosci 2000;12:1891-1899. (Pubitemid 30348828)
36. Buckley PF, Pillai A, Howell KR. Brain-derived neurotrophic factor: findings in schizophrenia. Curr Opin Psychiatry 2011;24:122-127.
37. Favalli G, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis ZJ. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res 2012;46:1-11.
38. Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004;24:10099-10102. (Pubitemid 39492034)
39. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005;15:319-329. (Pubitemid 40487736)
40. Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 2009;35:959-972.
41. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164:1557-1560. (Pubitemid 350069735)
42. Doré S, Kar S, Quirion R. Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proc Natl Acad Sci U S A 1997;94:4772-4777. (Pubitemid 27194319)
43. de Martino M, Galli L, Chiarelli F, Verrotti A, Rossi ME, Bindi G, et al. Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection. Clin Immunol 2000;94:212-218. (Pubitemid 30141749)
44. Hsiao EY, Patterson PH. Activation of the maternal immune system induces endocrine changes in the placenta via IL-6. Brain Behav Immun 2011;25:604-615.
45. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004;174:151-162. (Pubitemid 38925100)
46. Heckers S. The hippocampus in schizophrenia. Am J Psychiatry 2004;161:2138-2139.
47. Tamminga CA, Stan AD, Wagner AD. The hippocampal formation in schizophrenia. Am J Psychiatry 2010;167:1178-1193.
48. Lee E, Son H. Adult hippocampal neurogenesis and related neurotrophic factors. BMB Rep 2009;42:239-244.
49. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376. (Pubitemid 28467565)
50. Broca P. Rapport sur un memoire de M. Armand de Fleury intitulé: De l'inegalité dynamique des deux hemisphères cerébraux. Bull Acad Med 1877;6:508-539.
51. Crow TJ. Cerebral asymmetry and the lateralization of language: core deficits in schizophrenia as pointers to the gene. Curr Opin Psychiatry 2004;17:97-106. (Pubitemid 38316757)
52. Cantalupo C, Hopkins WD. Asymmetric Broca's area in great apes. Nature 2001;414:505.
53. Gannon PJ, Holloway RL, Broadfield DC, Braun AR. Asymmetry of chimpanzee planum temporale: humanlike pattern of Wernicke's brain language area homolog. Science 1998;279:220-222. (Pubitemid 28103878)
54. Glasel H, Leroy F, Dubois J, Hertz-Pannier L, Mangin JF, Dehaene-Lambertz G. A robust cerebral asymmetry in the infant brain: the rightward superior temporal sulcus. Neuroimage 2011;58:716-723.
55. Buxhoeveden DP, Switala AE, Litaker M, Roy E, Casanova MF. Lateralization of minicolumns in human planum temporale is absent in nonhuman primate cortex. Brain Behav Evol 2001;57:349-358. (Pubitemid 33079279)
56. Moore JK, Guan YL. Cytoarchitectural and axonal maturation in human auditory cortex. J Assoc Res Otolaryngol 2001;2:297-311. (Pubitemid 34074312)
57. Chance SA, Casanova MF, Switala AE, Crow TJ, Esiri MM. Minicolumn thinning in temporal lobe association cortex but not primary auditory cortex in normal human ageing. Acta Neuropathol 2006;111:459-464.
58. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001;49:1-52. (Pubitemid 32451739)
59. Chance SA, Casanova MF, Switala AE, Crow TJ. Auditory cortex asymmetry, altered minicolumn spacing and absence of ageing effects in schizophrenia. Brain 2008;131:3178-3192.
60. Satz P, Green MF. Atypical handedness in schizophrenia: some methodological and theoretical issues. Schizophr Bull 1999;25:63-78. (Pubitemid 29104374)
61. Sommer I, Ramsey N, Kahn R, Aleman A, Bouma A. Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis. Br J Psychiatry 2001;178:344-351. (Pubitemid 32280929)
62. Dragovic M, Hammond G. Handedness in schizophrenia: a quantitative review of evidence. Acta Psychiatr Scand 2005;111:410-419. (Pubitemid 40776285)
63. Crow TJ. Is schizophrenia the price that Homo sapiens pays for language? Schizophr Res 1997;28:127-141. (Pubitemid 28055661)
64. Crow TJ. The 'big bang' theory of the origin of psychosis and the faculty of language. Schizophr Res 2008;102:31-52.
65. Oertel V, Knöchel C, Rotarska-Jagiela A, Schönmeyer R, Lindner M, van de Ven V, et al. Reduced laterality as a trait marker of schizophrenia-evidence from structural and functional neuroimaging. J Neurosci 2010;30:2289-2299.
66. Geschwind N, Galaburda AM. Cerebral lateralization: Biological mechanisms, associations, and pathology. Cambridge: MIT Press; 1987.
67. Geschwind N, Behan P. Left-handedness: association with immune disease, migraine, and developmental learning disorder. Proc Natl Acad Sci U S A 1982;79:5097-5100. (Pubitemid 12004170)
68. Chengappa KN, Cochran J, Rabin BS, Ganguli R. Handedness and autoantibodies. Lancet 1991;338:694.
69. Chengappa KN, Ganguli R, Ulrich R, Rabin BS, Cochran J, Brar JS, et al. The prevalence of autoantibodies among right and left handed schizophrenic patients and control subjects. Biol Psychiatry 1992;32:803-811.
70. Chengappa KN, Ganguli R, Yang ZW, Brar JS, Li L, Rabin BS. Left-handed first-episode, neuroleptic-naive schizophrenic patients have a higher prevalence of autoantibodies. Schizophr Res 1992;8:75-80.
71. Hassler M. Anomalous dominance, immune parameters, and spatial ability. Int J Neurosci 1993;68:145-156.
72. Hassler M, Gupta D. Functional brain organization, handedness, and immune vulnerability in musicians and non-musicians. Neuropsychologia 1993;31:655-660. (Pubitemid 23225382)
73. Morfit NS, Weekes NY. Handedness and immune function. Brain Cogn 2001;46:209-213. (Pubitemid 32466609)
74. Pennington BF, Smith SD, Kimberling WJ, Green PA, Haith MM. Left-handedness and immune disorders in familial dyslexics. Arch Neurol 1987;44:634-639. (Pubitemid 17073193)
75. Searleman A, Fugagli AK. Suspected autoimmune disorders and left-handedness: evidence from individuals with diabetes. Crohn's disease and ulcerative colitis. Neuropsychologia 1987;25:367-374. (Pubitemid 17080381)
76. Smith BD, Meyers MB, Kline R. For better or for worse: left-handedness, pathology, and talent. J Clin Exp Neuropsychol 1989;11:944-958. (Pubitemid 20052128)
77. McManus IC, Bryden MP. Geschwind's theory of cerebral lateralization: developing a formal, causal model. Psychol Bull 1991;110:237-253.
78. Berenbaum SA, Denburg SD. Evaluating the empirical support for the role of testosterone in the Geschwind-Behan-Galaburda model of cerebral lateralization: commentary on Bryden, McManus, and Bulman-Fleming. Brain Cogn 1995;27:79-83.
79. Pennell LM, Galligan CL, Fish EN. Sex affects immunity. J Autoimmun 2012;38:J282-J291.
80. Peeva E, Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 2005;101:123-143. (Pubitemid 41368071)
81. Kang DH, Davidson RJ, Coe CL, Wheeler RE, Tomarken AJ, Ershler WB. Frontal brain asymmetry and immune function. Behav Neurosci 1991;105:860-869.
82. Neveu PJ. Asymmetrical brain modulation of the immune response. Brain Res Brain Res Rev 1992;17:101-107.
83. Lengen C, Regard M, Joller H, Landis T, Lalive P. Anomalous brain dominance and the immune system: do left-handers have specific immunological patterns? Brain Cogn 2009;69:188-193.
84. Müller W, Groothuis TG, Kasprzik A, Dijkstra C, Alatalo RV, Siitari H. Prenatal androgen exposure modulates cellular and humoral immune function of black-headed gull chicks. Proc Biol Sci 2005;272:1971-1977. (Pubitemid 41414650)
85. Debnath M, Cannon DM, Venkatasubramanian G. Variation in the major histocompatibility complex [MHC] gene family in schizophrenia: associations and functional implications. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:49-62.
86. Wierzba-Bobrowicz T, Lewandowska E, Kosno-Kruszewska E, Lechowicz W, Pasennik E, Schmidt-Sidor B. Degeneration of microglial cells in frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 2004;42:157-165. (Pubitemid 39433401)
87. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006;112:305-316. (Pubitemid 44275885)
88. Billiards SS, Haynes RL, Folkerth RD, Trachtenberg FL, Liu LG, Volpe JJ, et al. Development of microglia in the cerebral white matter of the human fetus and infant. J Comp Neurol 2006;497:199-208. (Pubitemid 43825427)
89. Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008;60:430-440.
90. Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A. Glia: the fulcrum of brain diseases. Cell Death Differ 2007;14:1324-1335. (Pubitemid 46965262)
91. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci 2009;3:14.
92. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009;63:257-265.
93. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-671.
94. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009;50:1801-1807.
95. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:336-339. (Pubitemid 351178944)
96. Hashimoto K. Microglial activation in schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1758-1759; author reply 1760.
97. Hashimoto K. Abnormality of cerebral perfusion in the posterior cingulate gyrus of a refractory patient with schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1132; author reply 1133-1134.
98. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012;26:1185-1193.
99. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010;71:138-149.
100. Jhamnani K, Shivakumar V, Kalmady S, Rao NP, Venkatasubramanian G. Successful use of add-on minocycline for treatment of persistent negative symptoms in schizophrenia. J Neuropsychiatry Clin Neurosci 2013;25:E06-E07.
101. Romero E, Guaza C, Castellano B, Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry 2010;15:372-383.
102. Borrell J, Vela JM, Arévalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 2002;26:204-215. (Pubitemid 34093083)
103. Mcghie A, Chapman J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 1961;34:103-116.
104. Venables PH. Selectivity of attention, withdrawal, and cortical activation. Studies in chronic schizophrenia. Arch Gen Psychiatry 1963;9:74-78.
105. Williams TJ, Nuechterlein KH, Subotnik KL, Yee CM. Distinct neural generators of sensory gating in schizophrenia. Psychophysiology 2011;48:470-478.
106. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008;158:226-247.
107. Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 2006;32:692-700. (Pubitemid 44412856)
108. Kim SH, Lee JM, Kim HP, Jang DP, Shin YW, Ha TH, et al. Asymmetry analysis of deformable hippocampal model using the principal component in schizophrenia. Hum Brain Mapp 2005;25:361-369. (Pubitemid 41105591)
109. Qiu A, Wang L, Younes L, Harms MP, Ratnanather JT, Miller MI, et al. Neuroanatomical asymmetry patterns in individuals with schizophrenia and their non-psychotic siblings. Neuroimage 2009;47:1221-1229.
110. Lang TJ. Estrogen as an immunomodulator. Clin Immunol 2004;113:224-230. (Pubitemid 39422599)
111. Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 2005;16:46-52. (Pubitemid 40270849)
112. Paimela T, Hyttinen JM, Viiri J, Ryhänen T, Karvonen MK, Unkila M, et al. Influence of selective estrogen receptor modulators on interleukin-6 expression in human retinal pigment epithelial cells (ARPE-19). Eur J Pharmacol 2010;640:219-225.
113. Gingerich S, Kim GL, Chalmers JA, Koletar MM, Wang X, Wang Y, et al. Estrogen receptor α and G-protein coupled receptor 30 mediate the neuroprotective effects of 17β-estradiol in novel murine hippocampal cell models. Neuroscience 2010;170:54-66.
114. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007;72:381-405. (Pubitemid 46602478)
115. Meng JL, Ma YY, Luo HY, Kong SZ, He YW, Dong BC, et al . Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine. Sheng Li Xue Bao 2008;60:369-374.
116. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008;65:955-960.
117. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res 2001;48:137-144. (Pubitemid 32241189)
118. Kulkarni J, de Castella A, Headey B, Marston N, Sinclair K, Lee S, et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res 2011;125:278-283.
119. Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010;35:1142-1147.
120. Salvetti NR, Ortega HH, Veiga-Lopez A, Padmanabhan V. Developmental programming: impact of prenatal testosterone excess on ovarian cell proliferation and apoptotic factors in sheep. Biol Reprod 2012;87:22, 1-10.
121. Abi Salloum B, Herkimer C, Lee JS, Veiga-Lopez A, Padmanabhan V. Developmental programming: prenatal and postnatal contribution of androgens and insulin in the reprogramming of estradiol positive feedback disruptions in prenatal testosterone-treated sheep. Endocrinology 2012;153:2813-2822.
122. Kimura D. Sex, sexual orientation and sex hormones influence human cognitive function. Curr Opin Neurobiol 1996;6:259-263. (Pubitemid 26168486)
123. Sanders G, Wenmoth D. Verbal and music dichotic listening tasks reveal variations in functional cerebral asymmetry across the menstrual cycle that are phase and task dependent. Neuropsychologia 1998;36:869-874. (Pubitemid 28404314)
124. Doty RL, Kisat M, Tourbier I. Estrogen replacement therapy induces functional asymmetry on an odor memory/discrimination test. Brain Res 2008;1214:35-39.